DCM
LENZ

Discovery Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Discovery Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.21M Hold
241,300
– – 0.11% 64
2025
Q4 		$3.86M Buy
+241,300
New +$7.03M 0.21% 68

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Discovery Capital Management's LENZ Position: Q1 2026 in Review

Discovery Capital Management held its LENZ Therapeutics (LENZ) position steady in Q1 2026 at 241,300 shares worth $2.21M. The position accounts for 0.11% of the portfolio, ranked #64.

Discovery Capital Management first reported a position in LENZ in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.86M in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Discovery Capital Management held 241,300 shares of LENZ Therapeutics worth $2.21M as of Q1 2026.
  • Discovery Capital Management left its LENZ Therapeutics share count unchanged in Q1 2026.
  • LENZ Therapeutics made up 0.11% of Discovery Capital Management's portfolio in Q1 2026, its #64 holding.
  • Discovery Capital Management first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Discovery Capital Management's LENZ Therapeutics position peaked at $3.86M in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Discovery Capital Management's 13F filing for Q1 2026, filed 15 May 2026.